1. Home
  2. ACXP vs RNXT Comparison

ACXP vs RNXT Comparison

Compare ACXP & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACXP
  • RNXT
  • Stock Information
  • Founded
  • ACXP 2017
  • RNXT 2012
  • Country
  • ACXP United States
  • RNXT United States
  • Employees
  • ACXP N/A
  • RNXT N/A
  • Industry
  • ACXP Biotechnology: Pharmaceutical Preparations
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACXP Health Care
  • RNXT Health Care
  • Exchange
  • ACXP Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • ACXP 31.4M
  • RNXT 31.6M
  • IPO Year
  • ACXP 2021
  • RNXT 2021
  • Fundamental
  • Price
  • ACXP $0.78
  • RNXT $1.15
  • Analyst Decision
  • ACXP Strong Buy
  • RNXT Strong Buy
  • Analyst Count
  • ACXP 1
  • RNXT 2
  • Target Price
  • ACXP $12.00
  • RNXT $6.50
  • AVG Volume (30 Days)
  • ACXP 361.0K
  • RNXT 108.8K
  • Earning Date
  • ACXP 03-14-2025
  • RNXT 03-31-2025
  • Dividend Yield
  • ACXP N/A
  • RNXT N/A
  • EPS Growth
  • ACXP N/A
  • RNXT N/A
  • EPS
  • ACXP N/A
  • RNXT N/A
  • Revenue
  • ACXP N/A
  • RNXT N/A
  • Revenue This Year
  • ACXP N/A
  • RNXT N/A
  • Revenue Next Year
  • ACXP N/A
  • RNXT N/A
  • P/E Ratio
  • ACXP N/A
  • RNXT N/A
  • Revenue Growth
  • ACXP N/A
  • RNXT N/A
  • 52 Week Low
  • ACXP $0.68
  • RNXT $0.77
  • 52 Week High
  • ACXP $3.35
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • ACXP 46.10
  • RNXT 58.08
  • Support Level
  • ACXP $0.70
  • RNXT $1.32
  • Resistance Level
  • ACXP $0.82
  • RNXT $1.40
  • Average True Range (ATR)
  • ACXP 0.06
  • RNXT 0.11
  • MACD
  • ACXP 0.01
  • RNXT 0.00
  • Stochastic Oscillator
  • ACXP 40.10
  • RNXT 39.47

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: